Atossa Genetics Inc Stock Nasdaq
Stocks
US04962H2094
Biotechnology & Medical Research
| Market Cap | 25.75M 22.19M 20.8M 18.99M 35.77M 2.46B 35.89M 247M 96.29M 1.24B 96.67M 94.56M 4.12B | P/E 2026 * |
-0.67x | P/E 2027 * | -0.82x |
|---|---|---|---|---|---|
| Enterprise Value | 25.75M 22.19M 20.8M 18.99M 35.77M 2.46B 35.89M 247M 96.29M 1.24B 96.67M 94.56M 4.12B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
97.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Atossa Genetics Inc
| 1 day | +27.09% |
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 75 | 01/04/2009 |
Mark Daniel
DFI | Director of Finance/CFO | 50 | 14/10/2025 |
Janet Rose Rea
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Steven Quay
CHM | Chairman | 75 | 01/04/2009 |
Shu-Chih Chen
BRD | Director/Board Member | 64 | 01/04/2009 |
Stephen Galli
BRD | Director/Board Member | 79 | 01/07/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +27.09% | -30.98% | - | - | 25.75M | |
| -1.01% | -1.97% | +0.91% | +17.86% | 50.47B | |
| -2.03% | -3.49% | +416.54% | +501.09% | 44.56B | |
| -1.12% | -1.28% | +39.82% | +15.40% | 43.08B | |
| -2.92% | -4.56% | +6.91% | +71.04% | 41.7B | |
| -0.31% | -0.83% | +19.47% | +48.24% | 33.21B | |
| -1.57% | -5.65% | +23.59% | +116.46% | 16.77B | |
| +7.00% | +6.15% | - | - | 16.28B | |
| -0.39% | -1.56% | +10.99% | +26.88% | 14.58B | |
| -0.90% | -3.94% | +77.88% | +38.69% | 13.92B | |
| Average | +2.39% | -1.39% | +74.52% | +104.46% | 30.51B | |
| Weighted average by Cap. | -0.90% | -1.21% | +88.65% | +121.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -34.89M -30.07M -28.19M -25.73M -48.48M -3.33B -48.63M -334M -130M -1.68B -131M -128M -5.58B | -38.03M -32.77M -30.72M -28.04M -52.83M -3.63B -53M -364M -142M -1.83B -143M -140M -6.08B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
